Company / Operating Income per Share
Allogene Therapeutics, Inc. Operating Income per Share History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income per Share
-$0.99
FY2025
5-year range
-$1.94 / -$0.99
FY2021-FY2025
Trend
+49.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Income per Share returned to growth in FY2025 after 2 years of decline, reaching $-0.99.
Based on SEC 10-K filings.
-0.99 in FY2025.
Improved from $-1.26 to $-0.99 over the past 2 years.
Operating Income per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating income per share increased 49.2% year-over-year.
- Lowest operating income per share in the period was in FY2024.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -4.27 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Income per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.99 | +49.2% |
| FY2024 | -$1.94 | -54.8% |
| FY2023 | -$1.26 | -14.3% |
| FY2022 | -$1.10 | +23.6% |
| FY2021 | -$1.44 | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026